SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Axa SA (ADR) (OTCMKTS:AXAHY) managed to end the last trading session in a positive note with a negligible gain of 0.15% but the signal from the price action was anything but bullish. The volume of the day at 157,000 was much higher than the daily average of 111,000. The price action of the day created a Graveyard Doji candle pattern, with obvious bearish indications. The closing price of the day was coincident with the day low of $25.97, with clear price rejection seen at the higher levels. If the bulls fail to make a break above $26.30 by the next session, panic selling may set in.

AXAHY

Axa SA (ADR)(OTCMKTS:AXAHY) reported the financial report for the first half of FY2015 in August 2015 following which its stock witnessed a sharp drop in late August. After consolidating in September, Axa stock made a successful attempt to move north on the chart.

The view

Expressing his view on the performance in the first half of 2015, Henri de Castries, the CEO and Chairman of Axa, said that 1H2015 proved to be very strong period for AXA. He termed the first half of 2015 as a period of growth in earnings, revenues and phase of continuing transformation of the unit to face the new challenges. The revenues are advancing in the three big segments of the activity, including Life and Savings and Health & Protection.

The expert view

Castries stated that revenues are increasing in P&C unit, even if the respective cycle is now more challenging and the growth there is not noteworthy. Asset gathering and revenues are surging on the asset management aspect of the operations, where the net flows are reaching the highest levels ever for AXA SA for a semester. This period marks progression in profits because earnings per share on an adjusted basis grew by 12% which supports future dividend capacity.

The achievements

The CEO of Axa further called the first two quarter of fiscal as a period of continuing transformation along a couple of lines. The first one is the geographical aspect where the company completed some agreements in emerging nations: Egypt for company’s General and Life businesses and Brazil for commercial lines. Axa accomplished significant things in mature nations with the news of the Genworth acquisition. It is going to support company boost its Protection offer in numerous countries. The 1H2015 market the period of transformation for Axa, particularly on the digital and data unit as it witnessed launch of the Innovation Labs.